Nanoformulations for topical and systemic fat reduction and uses thereof

Abstract

The present invention provides nanoformulations for topical and systemic fat reduction and uses thereof. The nano preparation consists of an oil phase and a water phase. The oil phase is selected from triglyceride and other membrane material components, an oxidative stress inhibitor vitamin E, an endoplasmic reticulum UPR pathway inhibitor and the like, and the water phase is selected from a vitamin C deionized water solution and the like. According to the nano preparation, the endoplasmic reticulum stress inhibitor is entrapped in the carrier containing the oxidative stress inhibitor, so that the fat differentiation of precursor cells and the oxidative stress and the endoplasmic reticulum stress which are necessary in the maturation process of fat cell accumulated lipid are weakened, the new fat source is greatly reduced, and the overgrowth of the existing fat cells is inhibited; the purpose of efficient and safe slimming is achieved. Different purposes of local and / or systemic fat reduction can be realized due to different administration modes, administration sites and administration dosages. In addition, the traditional Chinese medicine also has a certain effect on preventing / treating fatty liver. The method is reasonable in design, easy to prepare, safe, efficient and easy to popularize.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to a nano preparation for local and systemic fat reduction and its application. It is a new type of nano-preparation that can be used for local or systemic weight loss and prevention and treatment of fatty liver. It can reduce the total amount of adipocytes and the storage of lipid droplets in adipocytes in adipose tissue and organs in the body, treat obesity syndrome and ensure the slimness of patients. It is used in medical beauty and medical weight loss and fatty liver treatment. Background technique [0002] Obesity, especially excessive obesity, has seriously plagued human health and quality of life, and has increasingly become one of the heterogeneous non-communicable epidemics sweeping Europe and the United States and other countries. Although obesity itself is not fatal, as a recognized risk factor, it is often associated with a variety of devastating diseases, leading to serious comp...

AI Technical Summary

Problems solved by technology

Among these drugs, except for orlistat, which reduces the intestinal absorption of ingested fat, it is more harmful to the gastrointestinal tract, liver and kidney [Arch Intern Med,2011,171(7):702-710 ], and most of the remaining drugs work by inhibiting the central nervous system pathway to reduce appetite or enhance satiety, so there are some predictable side effects, even side effects similar to stimulants or sedatives [Nat RevEndocrinol, 2018 ,14(1):12-24]

At present, only Kybella (ATX-101) is the only local fat-dissolving drug approved by FDA, which uses the surface activity of its main active ingredient deoxycholic acid to indiscriminately destroy all local tissue cells including fat cells, achieving Local fat-melting effect [Nat Rev Drug Discov,2016,15(2):73-76], so its safety and biocompatibility issues still cannot be ignored

At the same time, in general, the effects of local fat reduction and systemic weight loss are not compatible among the current FDA-approved drugs, that is, in the heterogeneous obese population, no drug has shown a generally applicable safe and efficient local and systemic fat reduction

Images